GRITTI, GIUSEPPE
 Distribuzione geografica
Continente #
AS - Asia 1.877
NA - Nord America 1.362
EU - Europa 723
SA - Sud America 320
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.322
Nazione #
US - Stati Uniti d'America 1.295
SG - Singapore 562
VN - Vietnam 481
CN - Cina 390
BR - Brasile 265
HK - Hong Kong 249
IT - Italia 209
RU - Federazione Russa 148
SE - Svezia 68
DE - Germania 67
IE - Irlanda 63
KR - Corea 61
GB - Regno Unito 40
CA - Canada 36
ID - Indonesia 28
UA - Ucraina 27
IN - India 24
AR - Argentina 22
MX - Messico 22
ZA - Sudafrica 21
BD - Bangladesh 18
ES - Italia 15
FI - Finlandia 14
PL - Polonia 14
TR - Turchia 14
JP - Giappone 13
FR - Francia 11
NL - Olanda 10
AT - Austria 8
EC - Ecuador 8
MA - Marocco 8
SA - Arabia Saudita 6
PK - Pakistan 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
CH - Svizzera 4
CL - Cile 4
CO - Colombia 4
IQ - Iraq 4
KE - Kenya 4
LB - Libano 4
PT - Portogallo 4
PY - Paraguay 4
UY - Uruguay 4
EG - Egitto 3
KZ - Kazakistan 3
PE - Perù 3
AZ - Azerbaigian 2
BB - Barbados 2
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
LT - Lituania 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
RO - Romania 2
RS - Serbia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DM - Dominica 1
DO - Repubblica Dominicana 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
MY - Malesia 1
NI - Nicaragua 1
SI - Slovenia 1
SR - Suriname 1
TW - Taiwan 1
Totale 4.322
Città #
Singapore 302
Hong Kong 248
Ashburn 205
Ho Chi Minh City 157
Hefei 136
Hanoi 126
Ann Arbor 97
New York 63
Chandler 62
Dublin 60
Seoul 60
Milan 58
Los Angeles 56
Beijing 48
Woodbridge 42
Santa Clara 39
Fairfield 38
Frankfurt am Main 38
The Dalles 37
Dallas 32
São Paulo 32
Wilmington 27
Houston 26
Jakarta 23
Buffalo 22
Moscow 20
Seattle 20
Princeton 18
Denver 17
Haiphong 16
Lissone 16
Quận Bình Thạnh 15
Absecon 14
Ha Long 14
Jacksonville 14
Warsaw 14
Brooklyn 13
Cambridge 13
Johannesburg 13
Shanghai 13
London 12
Poplar 12
Tokyo 12
Chicago 11
Da Nang 11
Montreal 11
Tianjin 10
Vũng Tàu 10
Dearborn 9
Stockholm 9
Thái Nguyên 9
Toronto 9
Genoa 8
Lawrence 8
Atlanta 7
Biên Hòa 7
Boston 7
Bắc Giang 7
Mexico City 7
Munich 7
Nuremberg 7
Phoenix 7
Altamura 6
Bergamo 6
Brasília 6
Chennai 6
Hải Dương 6
Manchester 6
Mumbai 6
Phủ Lý 6
Quận Sáu 6
Rio de Janeiro 6
Rome 6
San Diego 6
Andover 5
Arezzo 5
Belo Horizonte 5
Brescia 5
Bắc Ninh 5
Curitiba 5
Dhaka 5
Dong Ket 5
Fremont 5
Lappeenranta 5
Miami 5
Ninh Bình 5
Salt Lake City 5
Shijiazhuang 5
Turku 5
Vienna 5
Vĩnh Tường 5
Amsterdam 4
Ankara 4
Brussels 4
Cagliari 4
Calgary 4
Casablanca 4
Contagem 4
Florence 4
Guangzhou 4
Totale 2.654
Nome #
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 374
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study 250
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 228
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 205
Development of new therapeutic strategies in mature T-cell non-Hodgkin lymphomas 205
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia 202
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial 198
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 193
Skip pattern approach toward the early access of innovative anticancer drugs 173
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 149
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 144
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 126
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 105
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy 104
High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma 97
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma 88
Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab 84
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study 83
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL 82
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia 81
Spleen tyrosine kinase/FMS-Like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/ CB-659 79
Genetic and phenotypic attributes of splenic marginal zone lymphoma 78
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up 77
Chimeric antigen receptor T cells for gamma–delta T cell malignancies 76
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study 76
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences 72
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 72
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 71
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma 68
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C 63
DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface 63
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma 63
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis 62
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma 61
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 60
Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure 55
SAKK38/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model 54
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma 45
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- And T-cell lymphoma models 44
Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell–redirected bispecific antibodies 40
Totale 4.450
Categoria #
all - tutte 13.927
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.927


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202195 0 0 0 0 0 19 8 15 13 21 5 14
2021/2022144 9 9 11 11 15 11 6 17 3 11 15 26
2022/2023209 25 53 25 15 12 34 8 10 20 1 3 3
2023/2024167 7 2 6 13 20 34 34 6 14 6 4 21
2024/20251.012 15 42 26 19 34 121 70 52 117 189 125 202
2025/20262.528 665 445 278 511 448 181 0 0 0 0 0 0
Totale 4.450